Risk factors

Vivid Seats relies heavily on Google traffic, single payment processor relations, and Hoya Topco governance control. The company faces extensive ticket resale regulations, potential acquisition integration risks, and cybersecurity threats.

Sagimet Biosciences faces heavy reliance on its lead drug candidate denifanstat for treating MASH.

SkinHealth Systems depends heavily on manufacturing and selling its Vortex-Fusion Delivery Systems and related consumable products.

Self-storage demand, competition, occupancy, rental rates, acquisitions, and geographic concentration dominate operating risks.

The company relies heavily on a small group of large wireless carrier customers for its revenue. Substantial doubt exists regarding the company's ability to continue as a going concern without additional capital. The loss of a major U.S. Tier 1 customer contract in 2023 continues to impact financial results.

Advertising revenue sensitivity and economic downturn risks dominate the company's risk profile. Heavy reliance on debt financing creates significant operational and financial constraints. Network affiliations and FCC regulations heavily impact television station operations.

Tredegar's results depend heavily on raw material and energy costs like aluminum and resin. Tariffs on aluminum imports pose a significant supply chain threat. Customer concentration in PE Films threatens sales if major accounts falter.

Inventory shrink from theft and organized retail crime poses ongoing operational risks.

Single-project reliance on the Livengood Gold Project dominates the risk profile.

Upstream Bio relies entirely on the clinical and commercial success of its sole product candidate, verekitug, targeting inflammatory diseases. Substantial ongoing losses require significant future capital raises, risking equity dilution or partnership constraints. Development depends heavily on third-party manufacturers, clinical data accuracy, and favorable regulatory approvals in multiple global jurisdictions.

Upland Software faces heavy debt obligations with $293.7 million outstanding under a credit facility maturing in August 2026. International operations drive 29% of revenue while exposing the company to currency fluctuations and foreign tax risks. Significant net operating loss carryforwards of $244.5 million risk expiration or limitation under tax laws.

Direct selling model faces heavy regulatory scrutiny across international markets, especially China.